AXLA

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Unity Biotechnology (UBX – Research Report) and Axcella Health (AXLA – Research Report) with bullish sentiments. Unity Biotechnology (UBX) Wedbush analyst Andreas Argyrides maintained a Buy rating on Unity Biotechnology today and set a price target of $36.00. The company's shares closed last Tuesday at $2.75, close to its 52-week low of $2.46. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-unity-biotechnology-ubx-and-axcella-health-axla?utm_source=advfn.com&utm_medium=referral